Among TKIs used in combination with ICIs for advanced RCC, lenvatinib has selective inhibitory activities mainly towards vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) receptors, thus tumor angiogenesis and malignant progression are strongly suppressed by inhibiting both pathways. Here, VEGFA is linked to renal cell carcinoma.